Optimizing biomarker development for clinical studies at the lead optimization stage of drug development

被引：0
|
作者：
Ginsburg, Geoffrey S. [1 ,2 ]
Lekstrom-Himes, Julie [2 ]
Trepicchio, William [2 ]
机构：
[1] Duke Univ, Inst Genome Sci & Policy, Ctr Genom Med, Durham, NC 27708 USA
[2] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
来源：
OPTIMIZING THE DRUG-LIKE PROPERTIES OF LEADS IN DRUG DISCOVERY | 2006年 / 4卷
关键词：
biomarkers; proof of concept; proof of mechanism; efficacy; toxicity; pharmacogenomics; pharmacogenetics; pharmacokinetics; drug metabolizing enzyme;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：411 / +
页数：3
相关论文
共 50 条
  • [1] Considerations for drug development biomarker assays in the clinical laboratory
    Arnold, Mark E.
    Allinson, John L.
    Piccoli, Steven P.
    [J]. BIOANALYSIS, 2023, 15 (10) : 533 - 536
  • [2] Biomarker development in drug discovery and development
    Shinagawa, Akira
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 54P - 54P
  • [3] The development of composite circulating biomarker models for use in anticancer drug clinical development
    Lancashire, Lee J.
    Roberts, Darren L.
    Dive, Caroline
    Renehan, Andrew G.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (08) : 1843 - 1851
  • [4] BIOMARKER DEVELOPMENT: ITS ROLE IN CLINICAL RESEARCH AND DRUG SAFETY
    Farre, M.
    Lucena, M. I.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 23 - 23
  • [5] Lipidomics in drug and biomarker development
    Wenk, Markus R.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (07) : 723 - 736
  • [6] How to synchronize biomarker development with early drug development?
    Harris, AL
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 26 - 26
  • [7] Optimizing drug development in oncology by clinical trial simulation: Why and how?
    Gal, Jocelyn
    Milano, Gerard
    Ferrero, Jean-Marc
    Saada-Bouzid, Esma
    Viotti, Julien
    Chabaud, Sylvie
    Gougis, Paul
    Le Tourneau, Christophe
    Schiappa, Renaud
    Paquet, Agnes
    Chamorey, Emmanuel
    [J]. BRIEFINGS IN BIOINFORMATICS, 2018, 19 (06) : 1203 - 1217
  • [8] Antiprogestin drug development: in vitro validation of a potential clinical biomarker.
    Gilles, Erard
    Caplier, Laura
    Valent, Alexander
    Serin, Guillaume
    Gompel, Anne
    Bosq, Jacques
    Zukiwski, Alexander
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [9] Lead optimization and drug development of antiproliferative constituents from Phyllanthus poilanei
    Huntsman, Andrew
    Young, Alexandria
    Woodard, John
    Chai, Hee-Byung
    Ren, Yulin
    Phelps, Mitch
    Kinghorn, Alan
    Burdette, Joanna
    Fuchs, James
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [10] MOVING CLINICAL DRUG DEVELOPMENT TO EARLY-STAGE DISEASE
    Berns, B.
    [J]. EJC SUPPLEMENTS, 2007, 5 (09): : 46 - 48
12345